Neoadjuvant Chemotherapy for Locally Advanced Colorectal Cancer
Results from the Phase 3 NeoCol Trial
Results from the Phase 3 NeoCol Trial
At the 2023 ASCO Annual Meeting, Lars Henrik Jensen, MD, University Hospital of Southern Denmark, Vejle, Denmark, shares results from the phase 3 NeoCol trial evaluating the addition of neoadjuvant chemotherapy to initial surgery for patients with locally advanced colon cancer.
In this trial, there was no significant difference in disease-free survival or overall survival between patients treated with neoadjuvant chemotherapy and those treated with standard upfront surgery. However, in chemotherapy cycles, postoperative complications, and downstaging, patients who received neoadjuvant chemotherapy seemed to have more favorable outcomes. Dr Jensen and coauthors concluded, "neoadjuvant chemotherapy could be considered a viable treatment option for patients with locally advanced colon cancer."
Source:
Jensen LH, Kjaer ML, Larsen FO, et al. Phase III randomized clinical trial comparing the efficacy of neoadjuvant chemotherapy and standard treatment in patients with locally advanced colon cancer: The NeoCol trial. Presented at 2023 ASCO Annual Meeting; June 2-6, 2023; Chicago, IL. Abstract LBA 3503.
